Albuminuria-lowering effect of adding semaglutide on top of empagliflozin in individuals with type 2 diabetes: A randomized and placebo-controlled study.
Suvanjaa SivalingamVictor Soendergaard WasehuusViktor Rotbain CurovicMartin Baek BlondTine Willum HansenFrederik PerssonEllen BurgessPublished in: Diabetes, obesity & metabolism (2023)
Semaglutide added to empagliflozin did not change UACR, measured GFR, 24-hour systolic blood pressure, body weight or plasma renin levels in individuals with T2D and albuminuria. Semaglutide improved glycaemic control and plasma aldosterone levels compared to placebo.